Filter by:
Muscular Dystrophy
October 2025
World Muscle Society 2025
LYNX Phase 2 Trial Results in DMD: Positive Effects of Sevasemten, an Investigational Agent, on Physical Function Defines Dose and Informs Design for Phase 3
Muscular Dystrophy
October 2025
World Muscle Society 2025
Trajectory of North Star Ambulatory Assessment with Sevasemten Compares Favorably to Natural History Modeling in Becker Muscular Dystrophy
Muscular Dystrophy
October 2025
World Muscle Society 2025
CANYON Trial Results: Sevasemten, an Investigational Fast Skeletal Myosin Inhibitor, Reduced Muscle Damage Biomarkers and Stabilized Function in BMD
Muscular Dystrophy
October 2025
World Muscle Society 2025
Breakthroughs in Becker: Unveiling New Natural History Insights and a Novel Agent’s Clinical Progress
Cardiovascular
September 2025
International Workshop on Cardiomyopathies
Plenary Presentation: CIRRUS-HCM: A Multiple-Dose Phase 2 Study of Safety, Tolerability, and Effects and Functional Capacity of the Novel Cardiac Sarcomere Modulator EDG-7500 in Hypertrophic Cardiomyopathy
Cardiovascular
September 2025
International Workshop on Cardiomyopathies
EDG-7500 in Hypertrophic Cardiomyopathy
Cardiovascular
September 2025
International Workshop on Cardiomyopathies
CIRRUS-HCM: A Multiple-Dose Phase 2 Study of Safety, Tolerability, and Effects on Hemodynamics and Functional Capacity of the Novel Cardiac Sarcomere Modulator EDG-7500 in Hypertrophic Cardiomyopathy
Muscular Dystrophy
June 2025
European Medical Journal
Understanding Becker Muscular Dystrophy: Disease Overview & Natural History
Muscular Dystrophy
June 2025
Muscle & Nerve
